A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.

Trial Profile

A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 01 Sep 2017 According to a TG Therapeutics media release, Patient characteristics, safety, and preliminary results of this trial will be presented at the upcoming 7th Joint ECTRIMS ACTRIMS meeting.
    • 09 Aug 2017 According to a TG Therapeutics media release, the company expects to present updated clinical data from this trial in 2017.
    • 27 Jun 2017 Preliminary results (n=23) assessing optimal dose and infusion time as well as safety and tolerability, presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top